HC Wainwright Brokers Increase Earnings Estimates for ASMB

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Research analysts at HC Wainwright lifted their Q2 2027 EPS estimates for shares of Assembly Biosciences in a report issued on Wednesday, September 9th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will earn ($0.83) per share for the quarter, up from their prior estimate of ($0.86). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $2.28 per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q3 2027 earnings at ($0.84) EPS, Q4 2027 earnings at $1.67 EPS, FY2027 earnings at $0.05 EPS and FY2029 earnings at ($2.22) EPS.

ASMB has been the subject of a number of other research reports. Mizuho set a $53.00 target price on Assembly Biosciences in a research note on Tuesday, September 1st. Zacks Research upgraded shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. UBS Group initiated coverage on shares of Assembly Biosciences in a research note on Tuesday, September 1st. They set a “buy” rating and a $52.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Assembly Biosciences has an average rating of “Moderate Buy” and an average price target of $45.60.

Assembly Biosciences Trading Down 7.3%

Shares of Assembly Biosciences stock opened at $30.46 on Friday. Assembly Biosciences has a twelve month low of $20.23 and a twelve month high of $39.71. The stock has a market cap of $620.17 million, a price-to-earnings ratio of 29.86 and a beta of 1.13. The company has a fifty day moving average price of $29.73 and a 200 day moving average price of $28.38.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. The business had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%.

Institutional Investors Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of ASMB. Bank of America Corp DE lifted its position in shares of Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the last quarter. California State Teachers Retirement System acquired a new stake in Assembly Biosciences during the second quarter valued at approximately $103,000. Seven Fleet Capital Management LP bought a new position in Assembly Biosciences during the 4th quarter worth approximately $147,000. Acadian Asset Management LLC lifted its holdings in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Assembly Biosciences in the 4th quarter worth approximately $228,000. Institutional investors own 19.92% of the company’s stock.

Key Stories Impacting Assembly Biosciences

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: Analysts raised long-term earnings estimates. HC Wainwright increased its FY2028 EPS forecast to $0.84 from $0.80 and its FY2030 forecast to $3.32 from $3.28. The firm maintained a Buy rating and a $50 price target, implying confidence in Assembly Biosciences’ longer-term growth prospects. MarketBeat analyst estimates
• Positive Sentiment: Gilead partnership economics could improve program funding. Assembly exercised an option to share U.S. development costs and profits for its herpes program with Gilead. Cost-sharing may reduce Assembly’s financial burden while preserving participation in potential commercial upside. Assembly exercises option with Gilead
• Neutral Sentiment: Management will present at the H.C. Wainwright Global Investment Conference on September 16. The presentation could provide updates on the company’s viral- and liver-disease programs, but the announcement itself does not include new clinical or financial data. Assembly conference presentation announcement
• Neutral Sentiment: Short-interest data offers no meaningful signal. Reported short interest was zero shares as of September 10, unchanged from the prior period, with a zero-day short-interest ratio. The accompanying claim of a “large increase” appears inconsistent with the figures and should not be interpreted as evidence of significant short selling.
• Negative Sentiment: No immediate catalyst accompanied the positive analyst revisions. With the conference still several days away and no new trial results or regulatory decision disclosed, investors may be taking profits or waiting for additional evidence before assigning greater value to the pipeline.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.